# Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

> **NCT03180294** · PHASE2 · COMPLETED · sponsor: **NRG Oncology** · enrollment: 230 (actual)

## Conditions studied

- Breast Carcinoma
- Cervical Carcinoma
- Ovarian Carcinoma
- Postmenopausal
- Uterine Corpus Cancer
- Vaginal Carcinoma
- Vulvar Carcinoma

## Interventions

- **DRUG:** Bupropion 150 mg XL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03180294
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-31
- **Primary completion:** 2021-02-22
- **Final completion:** 2021-02-22
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03180294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03180294, "Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03180294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*